Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant

There is a strong biologic rationale that poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors may benefit a broader range of metastatic breast cancer (MBC) patients than covered by current approvals, which require a germline BRCA1/2 sequence variant affecting function. We report a patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuemmel, Sherko, Harrach, Hakima, Schmutzler, Rita K., Kostara, Athina, Ziegler-Löhr, Katja, Dyson, Mark H., Chiari, Ouafaa, Reinisch, Mattea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382468/
https://www.ncbi.nlm.nih.gov/pubmed/32728620
http://dx.doi.org/10.1038/s41523-020-00174-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382468/
https://www.ncbi.nlm.nih.gov/pubmed/32728620
http://dx.doi.org/10.1038/s41523-020-00174-9

Ejemplares similares